News | February 21, 2022
Corbevax receives EUA for 12-18 age group
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Darolutamide is developed jointly by Bayer and Orion Corporation
Resolv ER may remedy leading causes of blindness in adults
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
It is being developed by Pune-based Gennova Biopharmaceuticals
Subscribe To Our Newsletter & Stay Updated
